ENZYME THERAPY FOR DISEASES INVOLVING ACTIVE OXYGEN

超氧化物歧化酶(SOD)已被 聚乙二醇单甲氧基共价键合形成 聚乙二醇-超氧化物歧化酶具有显著改善的药代动力学和 临床上没有显著的免疫原性。第一阶段试验已经完成 在人类志愿者中完成，没有不良反应报告。 聚乙二醇超氧化物歧化酶将在三个月的第二阶段临床试验中进行评估 适应症：肾移植、烧伤、多发性创伤。在……上面 完成第二阶段试验，我们将进入第三阶段试验 对于这些适应症。

The enzyme superoxide dismutase (SOD) has been modified by the covalent attachment of monomethoxypolyethylene glycol (PEG) to form the conjugate PEG-SOD with greatly improved pharmacokinetics and clinically insignificant immunogenicity. Phase I trials have been completed in human volunteers with no adverse effects reported. PEG-SOD will be in evaluated in Phase II clinical trials for three indications: kidney transplants, burns, and multiple trauma. On completion of Phase II trials, we will move to Phase III trials for these indications.